Loading
A phase 3 trial testing Quemliclustat in pancreatic ductal adenocarcinoma, active and no longer recruiting.
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma is a phase 3 interventional study registered as NCT06608927, led by Arcus Biosciences with Taiho Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma. Planned enrolment is 610 participants (estimated). The study started in 2024-12-13 and primary completion is expected in 2030-11-30. No results have been posted on ClinicalTrials.gov.